EMEA-003423-PIP02-23 - paediatric investigation plan

volrustomig

Key facts

• Active substance:
  volrustomig
• Therapeutic area:
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
• Decision number:
  P/0070/2024
• PIP number:
  EMEA-003423-PIP02-23
• Pharmaceutical form(s):
  Concentrate for solution for injection/infusion
• Condition(s) / indication(s):
  Treatment of head and neck epithelial malignant neoplasms
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  08/03/2024
• Compliance check done:
  No

Decision

P/0070/2024 : EMA decision of 8 March 2024 on the granting of a product specific waiver for volrustomig (EMEA-003423-PIP02-23)

Adopted Reference Number: EMA/28240/2024